Significant risk and associated factors of active tuberculosis infection in Korean patients with inflammatory bowel disease using anti-TNF agents

World Journal of Gastroenterology

Volumn 21, Issue 11, 2015, Pages 3308-3316

  Kim, Eun Soo ^a   Song, Geun Am ^b   Cho, Kwang Bum ^a   Park, Kyung Sik ^a   Kim, Kyeong Ok ^c   Jang, Byung Ik ^c   Kim, Eun Young ^d   Jeon, Seong Woo ^e   Lee, Hyun Seok ^a   Yang, Chang Heon ^f   Lee, Yong Kook ^f   Lee, Dong Wook ^d   Kim, Sung Kook ^e   Kim, Tae Oh ^g   Lee, Jonghun ^h   Kim, Hyung Wook ^b   Jee, Sam Ryong ^g   Park, Seun Ja ⁱ   Kim, Hyun Jin ^e,j  

^a Keimyung University   (South Korea)

^b Pusan National University   (South Korea)

^c Yeungnam University   (South Korea)

^d Catholic University of Daegu   (South Korea)

^e Kyungpook National University   (South Korea)

^f Dongguk University   (South Korea)

^g Inje University   (South Korea)

^h Dong A University   (South Korea)

ⁱ Kosin University   (South Korea)

^j Gyeongsang National University   (South Korea)

more..

Author keywords

Anti TNF; Inflammatory bowel disease; Korea; Latent tuberculosis infection; Risk factor; Tuberculosis

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; INFLIXIMAB; ISONIAZID; ISONIAZID PLUS RIFAMPICIN; MERCAPTOPURINE; STEROID; TUBERCULOSTATIC AGENT; TUMOR NECROSIS FACTOR INHIBITOR; ANTIINFLAMMATORY AGENT; TUMOR NECROSIS FACTOR ALPHA;

ABDOMINAL DISTENSION; ACUTE KIDNEY FAILURE; ADULT; ARTICLE; COUGHING; DYSPNEA; EXTRAPULMONARY TUBERCULOSIS; FATIGUE; FEMALE; FEVER; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; INFLAMMATORY BOWEL DISEASE; INTERFERON GAMMA RELEASE ASSAY; KOREAN (PEOPLE); LEUKOCYTE COUNT; LUNG LYMPH; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PLEURA; PROPHYLAXIS; SCREENING TEST; THORAX PAIN; THORAX RADIOGRAPHY; TUBERCULIN TEST; TUBERCULOSIS; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; CLINICAL TRIAL; COLITIS, ULCERATIVE; CROHN DISEASE; IMMUNOCOMPROMIZED PATIENT; IMMUNOLOGY; INCIDENCE; MICROBIOLOGY; MIDDLE AGED; MULTICENTER STUDY; OPPORTUNISTIC INFECTIONS; RETROSPECTIVE STUDY; RISK FACTOR; SOUTH KOREA; TERTIARY CARE CENTER; TREATMENT OUTCOME; YOUNG ADULT;

ADALIMUMAB; ADULT; ANTI-INFLAMMATORY AGENTS; COLITIS, ULCERATIVE; CROHN DISEASE; FEMALE; HUMANS; IMMUNOCOMPROMISED HOST; INCIDENCE; INFLIXIMAB; MALE; MIDDLE AGED; OPPORTUNISTIC INFECTIONS; REPUBLIC OF KOREA; RETROSPECTIVE STUDIES; RISK FACTORS; TERTIARY CARE CENTERS; TREATMENT OUTCOME; TUBERCULOSIS; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84925664502     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v21.i11.3308     Document Type: Article

References (38)

1. Van Assche G, Vermeire S, Rutgeerts P. Mucosal healing and anti TNFs in IBD. Curr Drug Targets 2010;11:227-233 [PMID: 20210770]
2. Yang SK, Yun S, Kim JH, Park JY, Kim HY, Kim YH, Chang DK, Kim JS, Song IS, Park JB, Park ER, Kim KJ, Moon G, Yang SH. Epidemiology of inflammatory bowel disease in the Songpa-Kangdong district, Seoul, Korea, 1986-2005: a KASID study. Inflamm Bowel Dis 2008;14:542-549 [PMID: 17941073 DOI: 10.1002/ibd.20310]
3. Lee KM, Jeen YT, Cho JY, Lee CK, Koo JS, Park DI, Im JP, Park SJ, Kim YS, Kim TO, Lee SH, Jang BI, Kim JW, Park YS, Kim ES, Choi CH, Kim HJ. Efficacy, safety, and predictors of response to infliximab therapy for ulcerative colitis: a Korean multicenter retrospective study. J Gastroenterol Hepatol 2013;28:1829-1833 [PMID: 23829336 DOI: 10.1111/jgh.12324]
4. Ye BD, Yang SK, Shin SJ, Lee KM, Jang BI, Cheon JH, Choi CH, Kim YH, Lee H. [Guidelines for the management of Crohn' s disease]. Korean J Gastroenterol 2012;59:141-179 [PMID: 22387837]
5. Choi CH, Kim YH, Kim YS, Ye BD, Lee KM, Lee BI, Jung SA, Kim WH, Lee H. [Guidelines for the management of ulcerative colitis]. Korean J Gastroenterol 2012;59:118-140 [PMID: 22387836]
6. Askling J, Fored CM, Brandt L, Baecklund E, Bertilsson L, Cöster L, Geborek P, Jacobsson LT, Lindblad S, Lysholm J, Rantapää-Dahlqvist S, Saxne T, Romanus V, Klareskog L, Feltelius N. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum 2005;52:1986-1992 [PMID: 15986370 DOI: 10.1002/art.21137]
7. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, Siegel JN, Braun MM. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098-1104 [PMID: 11596589 DOI: 10.1056/NEJMoa011110]
8. Mañosa M, Domènech E, Cabré E. Current incidence of active tuberculosis in IBD patients treated with anti-TNF agents: still room for improvement. J Crohns Colitis 2013;7:e499-e500 [PMID: 23689076 DOI: 10.1016/j.crohns.2013.04.021]
9. Jauregui-Amezaga A, Turon F, Ordás I, Gallego M, Feu F, Ricart E, Panés J. Risk of developing tuberculosis under anti-TNF treatment despite latent infection screening. J Crohns Colitis 2013;7:208-212 [PMID: 22677117 DOI: 10.1016/j.crohns.2012.05.012]
10. Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 2004;38:1261-1265 [PMID: 15127338 DOI: 10.1086/383317]
11. Gómez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 2003;48:2122-2127 [PMID: 12905464 DOI: 10.1002/art.11137]
12. Desai SB, Furst DE. Problems encountered during anti-tumour necrosis factor therapy. Best Pract Res Clin Rheumatol 2006;20:757-790 [PMID: 16979537 DOI: 10.1016/j.berh.2006.06.002]
13. WHO. Global Tuberculosis Report 2013. [Accessed on Sep. 2, 2014]. Available from: http://www.who.int/tb/publications/global-report/ed
14. Seong SS, Choi CB, Woo JH, Bae KW, Joung CL, Uhm WS, Kim TH, Jun. JB, Yoo DH, Lee JT, Bae SC. Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers. J Rheumatol 2007;34:706-711 [PMID: 17309133]
15. Theis VS, Rhodes JM. Review article: minimizing tuberculosis during anti-tumour necrosis factor-alpha treatment of inflammatory bowel disease. Aliment Pharmacol Ther 2008;27:19-30 [PMID: 17944997 DOI: 10.1111/j.1365-2036.2007.03553.x]
16. Clinical Practice Guidelines for Tuberculosis, Seoul, Korea: Korea Centers for Disease Control and Prevention, 2011. Accessed July 16, 2014. Available from: URL: http://www.lungkorea.org/image/mail/file 11017.pdf
17. Solovic I, Sester M, Gomez-Reino JJ, Rieder HL, Ehlers S, Milburn HJ, Kampmann B, Hellmich B, Groves R, Schreiber S, Wallis RS, Sotgiu G, Schölvinck EH, Goletti D, Zellweger JP, Diel R, Carmona L, Bartalesi F, Ravn P, Bossink A, Duarte R, Erkens C, Clark J, Migliori GB, Lange C. The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. Eur Respir J 2010;36:1185-1206 [PMID: 20530046 DOI: 10.1183/09031936.00028510]
18. Kim EM, Uhm WS, Bae SC, Yoo DH, Kim TH. Incidence of tuberculosis among korean patients with ankylosing spondylitis who are taking tumor necrosis factor blockers. J Rheumatol 2011;38:2218-2223 [PMID: 21844149 DOI: 10.3899/jrheum.110373]
19. Li X, Li T, Tan S. Males, ages ≥ 45 years, businessperson, floating population, and rural residents may be considered highrisk groups for tuberculosis infection in Guangzhou, China: a review of 136, 394 tb confirmed cases. Rev Inst Med Trop Sao Paulo 2013;55:366-368 [PMID: 24037294 DOI: 10.1590/S0036-46652013000500013]
20. Memish ZA, Bamgboye EA, Abuljadayel N, Smadi H, Abouzeid MS, Al Hakeem RF. Incidence of and risk factors associated with pulmonary and extra-pulmonary tuberculosis in Saudi Arabia (2010-2011). PLoS One 2014;9:e95654 [PMID: 24824783 DOI: 10.1371/journal.pone.0095654]
21. Vaughn BP, Doherty GA, Gautam S, Moss AC, Cheifetz AS. Screening for tuberculosis and hepatitis B prior to the initiation of anti-tumor necrosis therapy. Inflamm Bowel Dis 2012;18:1057-1063 [PMID: 21953829 DOI: 10.1002/ibd.21824]
22. Mow WS, Abreu-Martin MT, Papadakis KA, Pitchon HE, Targan SR, Vasiliauskas EA. High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy. Clin Gastroenterol Hepatol 2004;2:309-313 [PMID: 15067625]
23. Ponce De León D, Acevedo-Vásquez E, Sánchez-Torres A, Cucho M, Alfaro J, Perich R, Pastor C, Harrison J, Sánchez-Schwartz C. Attenuated response to purified protein derivative in patients with rheumatoid arthritis: study in a population with a high prevalence of tuberculosis. Ann Rheum Dis 2005;64:1360-1361 [PMID: 16100342 DOI: 10.1136/ard.2004.029041]
24. Mazurek GH, Jereb J, Vernon A, Lo Bue P, Goldberg S, Castro K. Updated guidelines for using Interferon Gamma Release Assays to detect Mycobacterium tuberculosis infection - United States, 2010. MMWR Recomm Rep 2010;59:1-25 [PMID: 20577159]
25. Song GG, Bae SC, Lee YH. Interferon-gamma release assays versus tuberculin skin testing in patients with rheumatoid arthritis. Int J Rheum Dis 2013;16:279-283 [PMID: 23981748 DOI: 10.1111/1756-185X.12098]
26. Papay P, Eser A, Winkler S, Frantal S, Primas C, Miehsler W, Novacek G, Vogelsang H, Dejaco C, Reinisch W. Factors impacting the results of interferon-γ release assay and tuberculin skin test in routine screening for latent tuberculosis in patients with inflammatory bowel diseases. Inflamm Bowel Dis 2011;17:84-90 [PMID: 20722065 DOI: 10.1002/ibd.21427]
27. Kim BJ, Choi YS, Jang BI, Park YS, Kim WH, Kim YS, Jung SA, Han DS, Kim JS, Choi JH, Choi CH, Jeen YT, Cheon JH, Ye BD, Yang SK, Kim YH. Prospective evaluation of the clinical utility of interferon-γ assay in the differential diagnosis of intestinal tuberculosis and Crohn's disease. Inflamm Bowel Dis 2011;17:1308-1313 [PMID: 21053248 DOI: 10.1002/ibd.21490]
28. Carmona L, Gómez-Reino JJ, Rodríguez-Valverde V, Montero D, Pascual-Gómez E, Mola EM, Carreño L, Figueroa M. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 2005;52:1766-1772 [PMID: 15934089 DOI: 10.1002/art.21043]
29. Winthrop KL. Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor. Nat Clin Pract Rheumatol 2006;2:602-610 [PMID: 17075599 DOI: 10.1038/ncprheum0336]
30. Sichletidis L, Settas L, Spyratos D, Chloros D, Patakas D. Tuberculosis in patients receiving anti-TNF agents despite chemoprophylaxis. Int J Tuberc Lung Dis 2006;10:1127-1132 [PMID: 17044206]
31. Choi JC, Lim SY, Suh GY, Chung MP, Kim H, Kwon OJ, Lee NY, Park YK, Bai GH, Koh WJ. Drug resistance rates of Mycobacterium tuberculosis at a private referral center in Korea. J Korean Med Sci 2007;22:677-681 [PMID: 17728509]
32. Lee SW, Jeon K, Kim KH, Min KH. Multidrug-resistant pulmonary tuberculosis among young Korean soldiers in a communal setting. J Korean Med Sci 2009;24:592-595 [PMID: 19654938 DOI: 10.3346/jkms.2009.24.4.592]
33. Rahier JF, Ben-Horin S, Chowers Y, Conlon C, De Munter P, D' Haens G, Domènech E, Eliakim R, Eser A, Frater J, Gassull M, Giladi M, Kaser A, Lémann M, Moreels T, Moschen A, Pollok R, Reinisch W, Schunter M, Stange EF, Tilg H, Van Assche G, Viget N, Vucelic B, Walsh A, Weiss G, Yazdanpanah Y, Zabana Y, Travis SP, Colombel JF. European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis 2009;3:47-91 [PMID: 21172250 DOI: 10.1016/j.crohns.2009.02.010]
34. Panaccione R, Ghosh S, Middleton S, Márquez JR, Scott BB, Flint L, Van Hoogstraten HJ, Chen AC, Zheng H, Danese S, Rutgeerts P. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology 2014;146:392-400.e3 [PMID: 24512909 DOI: 10.1053/j.gastro.2013.10.052]
35. Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, Lichtiger S, D'Haens G, Diamond RH, Broussard DL, Tang KL, Van Der Woude CJ, Rutgeerts P. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010;362:1383-1395 [PMID: 20393175 DOI: 10.1056/NEJMoa0904492]
36. Mert A, Bilir M, Tabak F, Ozaras R, Ozturk R, Senturk H, Aki H, Seyhan N, Karayel T, Aktuglu Y. Miliary tuberculosis: clinical manifestations, diagnosis and outcome in 38 adults. Respirology 2001;6:217-224 [PMID: 11555380]
37. Maartens G, Willcox PA, Benatar SR. Miliary tuberculosis: rapid diagnosis, hematologic abnormalities, and outcome in 109 treated adults. Am J Med 1990;89:291-296 [PMID: 2393033]
38. Wolfe F, Michaud K, Anderson J, Urbansky K. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum 2004;50:372-379 [PMID: 14872478 DOI: 10.1002/art.20009]